GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » ROE % Adjusted to Book Value

Endo (NDOI) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Endo ROE % Adjusted to Book Value?

Endo's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Endo's PB Ratio for the quarter that ended in Dec. 2024 was 1.49. Endo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 0.00%.

Endo ROE % Adjusted to Book Value Historical Data

The historical data trend for Endo's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo ROE % Adjusted to Book Value Chart

Endo Annual Data
Trend Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
- - -

Endo Quarterly Data
Jun23 Sep23 Dec23 Apr24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial - - Negative Equity -48.07 -

Competitive Comparison of Endo's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Endo's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endo's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Endo's ROE % Adjusted to Book Value falls into.


;
;

Endo ROE % Adjusted to Book Value Calculation

Endo's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 1.49
=0.00%

Endo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 1.49
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endo ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Endo's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
AMRX SUPN DVAX AMPH KNSA ANIP PCRX HROW NIKA BGM ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
N/A
Address
9 Great Valley Parkway, Malvern, PA, USA, 19355
Website
https://www.endo.com
Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.